AbstractGet full access to this articleView all access options for this article.Get accessReferences1.[GAO] U.S. Government Accountability Office. 2006. New drug development: Science, business, regulatory, and intellectual property issues cited as hampering drug development efforts. GAO: Washington, DC, 4.2.National Institutes of Health. 2008. Genetests: growth of laboratory directory. University of Washington: Seattle www.ncbi.nlm.nih.gov/projects/GeneTests/static/whatsnew/labdirgrowth.shtml. 2009 December 29.
